Identification
- Generic Name
- Vasomera
- DrugBank Accession Number
- DB16498
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- Pemziviptadil
- Vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein
- Vasomera
- External IDs
- PB1046
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Vasomera, developed by PhaseBio Pharmacetuicals Inc., is a long-acting analogue of vasoactive intestinal peptide (VIP). It has been used as an adjunctive therapy for treatment and prevention of cardiomyopathy and Duchenne Muscular Dystrophy, among others. Preclinical studies show vasomera allows for early diastolic relaxation, peripheral vasorelaxation, and reduction of inflammation and fibrosis. In June, 2020, PhaseBio Pharmaceuticals began a randomized, double-blind, parallel group study to explore vasomera efficacy in improving clinical outcomes of COVID-19 patients at high risk for ARDS and death (NCT04433546).
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Biopolymers
- Cardiovascular Agents
- Drug Carriers
- Drug Delivery Systems
- Elastin
- Experimental Unapproved Treatments for COVID-19
- Extracellular Matrix Proteins
- Gastrointestinal Hormones
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Macromolecular Substances
- Membrane Proteins
- Nerve Tissue Proteins
- Neuropeptides
- Peptide Hormones
- Peptides
- Pharmaceutical Preparations
- Polymers
- Protein Precursors
- Proteins
- Receptors, G-Protein-Coupled
- Receptors, Gastrointestinal Hormone
- Receptors, Neuropeptide
- Receptors, Neurotransmitter
- Receptors, Peptide
- Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide
- Scleroproteins
- Vasodilating Agents
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 200AW54D93
- CAS number
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Heart Failure 1 2 Terminated Treatment Acute Respiratory Distress Syndrome (ARDS) / Cardiac Complications / Cardiac Dysfunction / Cardiac Failure / Cardiovascular Events / Coronavirus Disease 2019 (COVID‑19) / Cytokine Storm / Hypoxemic Respiratory Failure / Hypoxic Respiratory Failure / Infections, Coronavirus / Myocardial Infarction / Pneumonia / Pulmonary Edemas / Pulmonary Inflammation / Respiratory complications, not elsewhere classified / Respiratory Failure / Respiratory Insufficiency 1 2 Terminated Treatment Pulmonary Arterial Hypertension (PAH) 2 1 Completed Treatment Hypertension, Essential Hypertension 2 1 Completed Treatment Pulmonary Arterial Hypertension (PAH) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at January 21, 2021 02:01 / Updated at November 20, 2023 20:11